EXEL - Exelixis, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
20.85
-0.29 (-1.37%)
At close: 4:00PM EDT

20.85 0.00 (0.00%)
After hours: 4:33PM EDT

Stock chart is not supported by your current browser
Previous Close21.14
Open21.14
Bid20.83 x 3100
Ask21.55 x 800
Day's Range20.74 - 21.40
52 Week Range13.42 - 25.31
Volume1,869,266
Avg. Volume3,009,246
Market Cap6.292B
Beta (3Y Monthly)1.77
PE Ratio (TTM)10.03
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Health Care Digest: How California's stem cell institute may help find glaucoma cure; a stealthy biotech with $100M; and more
    American City Business Journals3 days ago

    Health Care Digest: How California's stem cell institute may help find glaucoma cure; a stealthy biotech with $100M; and more

    The future of California's stem cell research funding agency is in doubt, but its impact goes far beyond the billions of dollars it has doled out to researchers, says the Glaucoma Research Foundation.

  • Read This Before You Buy Any New Cancer Drug Stocks
    Motley Fool3 days ago

    Read This Before You Buy Any New Cancer Drug Stocks

    Around $36 billion worth of biopharma acquisitions over the past few years suggests smaller might be better.

  • Oh, By the Way, This Clinical Trial Didn't Work
    Motley Fool6 days ago

    Oh, By the Way, This Clinical Trial Didn't Work

    Sometimes, you hear the bad news from a friend of a friend.

  • Exelixis Stock Is Up despite Disappointing Clinical Trial Results
    Market Realist6 days ago

    Exelixis Stock Is Up despite Disappointing Clinical Trial Results

    While Exelixis was down 5.9% in after-hours trading after the announcement of disappointing clinical trial results, the stock recovered the losses and closed at $21.14 yesterday, 0.81% higher than its previous close. Based on this price performance, it seems that shareholders had already priced in the trial's failure.

  • Dow Jones Futures: Canopy Growth, PayPal, Lululemon, Exelixis Active
    Investor's Business Daily6 days ago

    Dow Jones Futures: Canopy Growth, PayPal, Lululemon, Exelixis Active

    Stock futures: Canopy Growth reported a wider-than-expected Q4 loss. PayPal, Lululemon Athletica and Exelixis moved overnight on news.

  • Benzinga6 days ago

    The Daily Biotech Pulse: ContraVir's Volatile Ride Continues, Late-Stage Disappointment For Exelixis, Regeneron-Sanofi Breathe Easy

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 20) Abbott Laboratories (NYSE: ABT ) ANI Pharmaceuticals ...

  • Here’s What Hedge Funds Think About Exelixis, Inc. (EXEL)
    Insider Monkey7 days ago

    Here’s What Hedge Funds Think About Exelixis, Inc. (EXEL)

    Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying before the Q4 market crash that the stock market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the first […]

  • TheStreet.com8 days ago

    2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land

    "Merger Monday" finally lived up to its billing this week in Biotech Land. announced just before the opening bell Monday that it was acquiring oncology concern Array Biopharma Inc. Pfizer paid a buyout premium of more than 60% to purchase Array.

  • Markit17 days ago

    See what the IHS Markit Score report has to say about Exelixis Inc.

    Exelixis Inc NASDAQ/NGS:EXELView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for EXEL with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding EXEL totaled $321 million. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • MoneyShow20 days ago

    Exelixis Bets on Breakthroughs in Oncology

    Based in San Francisco, Exelixis (EXEL) is a drug company that is dedicated to the discovery, development and commercialization of new medicines for cancer treatment, asserts Mark Skousen, growth stock expert and editor of Five-Star Trader.

  • Top 5 Stocks in the Fight Against Cancer
    Motley Fool21 days ago

    Top 5 Stocks in the Fight Against Cancer

    These stocks are leading the way in their respective areas in battling cancer.

  • Why Is Exelixis (EXEL) Down 1% Since Last Earnings Report?
    Zacks27 days ago

    Why Is Exelixis (EXEL) Down 1% Since Last Earnings Report?

    Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Is Exelixis, Inc.'s (NASDAQ:EXEL) CEO Being Overpaid?
    Simply Wall St.28 days ago

    Is Exelixis, Inc.'s (NASDAQ:EXEL) CEO Being Overpaid?

    Michael Morrissey became the CEO of Exelixis, Inc. (NASDAQ:EXEL) in 2010. This analysis aims first to contrast CEO...

  • Dow 30 Stock Roundup: Home Depot Earnings Impress, Merck to Buy Peloton Therapeutics
    Zackslast month

    Dow 30 Stock Roundup: Home Depot Earnings Impress, Merck to Buy Peloton Therapeutics

    The index suffered a difficult week as investors braced for a protracted U.S.-China trade war.

  • Merck to Buy Private Cancer Drugmaker Peloton Therapeutics
    Zackslast month

    Merck to Buy Private Cancer Drugmaker Peloton Therapeutics

    Merck (MRK) signs a definitive agreement to buy small private biotech, Peloton Therapeutics for $1.05 billion in cash to boost its oncology pipeline.

  • Pfizer's Bavencio+Inlyta Combo Gets FDA Nod for Kidney Cancer
    Zackslast month

    Pfizer's Bavencio+Inlyta Combo Gets FDA Nod for Kidney Cancer

    Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets approval in the United States.

  • These 3 Value Stocks Are Absurdly Cheap Right Now
    Motley Foollast month

    These 3 Value Stocks Are Absurdly Cheap Right Now

    You have to look hard to see value in today's pricey market, but here are three inexpensive stocks that should be on your radar today.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of EXEL earnings conference call or presentation 1-May-19 9:00pm GMT

    Q1 2019 Exelixis Inc Earnings Call

  • Benzinga2 months ago

    Jim Cramer Weighs In On Zebra Technologies, Exelixis And More

    On CNBC's "Mad Money Lightning Round," Jim Cramer said Zebra Technologies Corp. (NASDAQ: ZBRA) is a fast-growing company and he is sticking by it because barcode technology is the way of the future. Cramer is not a buyer of EQM Midstream Partners LP (NYSE: EQM). Exelixis, Inc. (NASDAQ: EXEL) is a good spec, said Cramer.

  • Where Will Gilead Sciences Spend Its Cash?
    Motley Fool2 months ago

    Where Will Gilead Sciences Spend Its Cash?

    Atara Biotherapeutics and Exelixis might be top takeover targets for the biotech giant.

  • Exelixis Expands Its Sales
    Motley Fool2 months ago

    Exelixis Expands Its Sales

    The biotech produced solid top-line growth spurred by a new approval for Cabometyx.

  • Estimating The Fair Value Of Exelixis, Inc. (NASDAQ:EXEL)
    Simply Wall St.2 months ago

    Estimating The Fair Value Of Exelixis, Inc. (NASDAQ:EXEL)

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! How far off is Exelixis, Inc. (NASDAQ:EXEL) from its intrinsic value? Using the most recent financial...

  • Exelixis (EXEL) Earnings & Revenues Beat Estimates in Q1
    Zacks2 months ago

    Exelixis (EXEL) Earnings & Revenues Beat Estimates in Q1

    Exelixis's (EXEL) earnings and revenues beat expectations in the first quarter on strong sales of Cabometyx.